Vertex Pharmaceuticals Reports Strong Q2 Results, Raises Guidance
Vertex Pharmaceuticals (VRTX) reported strong second-quarter fiscal 2027 results with revenue reaching $3.3 billion—a 12% year-over-year increase—and non-GAAP earnings per share of $4.73, up by 5%. The company also raised its full-year revenue guidance to a top end of $13.2 billion and holds roughly $13.6 billion in cash and investments. VRTX shares have risen significantly this year due to strong institutional investor inflows and positive fundamentals. Institutional demand has driven the stock up by 32.4% over the past year, supported by a healthy financial track record including a three-year sales growth rate of +11.3%, profit margin of +32.7%, and expected EPS increase of +13.2%. The company is frequently highlighted in proprietary investment tools for its strong performance. The combination of solid fundamentals and institutional support has made Vertex Pharmaceuticals one of the top-rated stocks at MoneyFlows, with historical gains reaching 1,682% since 2008 due to repeated large-volume purchases by institutions. The stock is seen as a potential long-term winner for investors seeking strong growth opportunities.
Tickers: $VRTX
Topics: biotechnology institutional_investing pharmaceuticals stock_performance